NoelleGilletteClovenMD

Obstetrics & Gynecology • Fort Worth, TX

Gynecologic Oncology, Minimally Invasive / Endoscopic Surgery

Gynecologic Oncologist, Texas Oncology

Join to view full profile

Dr. Cloven is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cloven's full profile

Already have an account?

Office
500 S Henderson St
Ste 200
Fort Worth, TX 76104
Phone+1 972-997-8000

Fax+1 817-413-1499

Summary

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Can

N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1909707. [Epub ahead of print]

Education & Training

University of California (Irvine)Fellowship, Gynecologic Oncology, 1997 - 2001
University of California (Irvine)Residency, Obstetrics and Gynecology, 1993 - 1997
Baylor College of MedicineClass of 1993
University of TexasBA, Biology, 1985 - 1989

Certifications & Licensure

TX State Medical License 1994 - 2024
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Outstanding Preceptor UNT Health Science Center, PA studies, 2011-2017
Top Doctors Fort Worth Texas Magazine, 2011-2017
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Richard J. Taylor Award Creighton University, 2002
Best Poster Presentation Los Angeles OB/GYN Assembly, 2000
Junior Fellow American College of Obstetricians and Gynecologists, 1993
Janet M. Glasgow Memorial Achievement Citation American Medical Women's Association, 1993
Award in Pharmacology BUSCH, 1993
Outstanding Performance in Clinical Neurology 1993
Alpha Omega Alpha 1993
Honors for Performance in Basic Sciences 1990
Join now to see all

Clinical Trials

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin Start of enrollment: 2006 Apr 01
Withdrawn
Phase 2
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Start of enrollment: 2007 Sep 01
Terminated
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Oct 01
Completed
Phase 2
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer Start of enrollment: 2018 Oct 11
Active, not recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer Start of enrollment: 2019 Oct 03
Terminated
Phase 2
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer Start of enrollment: 2019 Jul 18
Active, not recruiting
Phase 3
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Start of enrollment: 2020 Jul 23
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

40 citations
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3...
Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva
Lancet. 2024-04-06
320 citations
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, David Miller, N.G. Cloven
The Lancet. Oncology. 2019-05-01
536 citations
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Robert L. Coleman, Gini F. Fleming, Mark F. Brady, Elizabeth M. Swisher, Karina Dahl Steffensen
The New England Journal of Medicine. 2019-09-28

Journal Articles

Velaparib with First-Line Chemotherapy and as Maintenance therapy in ovarian cancer
coleman, NEJM, 9/28/2019
We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies
Ronald D. Alvarez ; Heidi J. Gray ; Patrick F. Timmins ; Randall K. Gibb ; Mitchell Edelson ; Jeffrey M. Fowler ; Laura J. Havrilesky ; Dayna L. McCauley ; John D. Nas..., Gyncol Oncol, 1/1/2013
In Vitro Chemoresistance and Biomarker Profiles are Unique for Histologic Subtypes of Epithelial Ovarian Cancer
Gillette Cloven, N, Kyshtoobayeva A, Burger RA, Yu IN, Fruehaf JP., Gynecologic-Oncology, 1/1/2004
Bowel Resection during Primary Surgical Debulking for Epithelial Ovarian Cancer
Gillette Cloven N, Burger RA, Monk BJ, McMeekin DS, Vasilev S, DiSaia PJ, Kohler MF, J Am Coll Surg, 1/1/2001
Evaluation of D-Methionine as a Cytoprotectant in Cisplatin Treatment of an Animal Model for Ovarian Cancer
Gillette Cloven N, Re A, McHale M, Burger RA, DiSaia PJ, Rose GS, Campbell K, Fan H., Anticancer Research, 1/1/2000
Management of Ovarian-Cancer in Patients Older than Eighty
Gillette CN, Manetta A., Berman ML, Kohler MF, DiSaia PJ, Gynecol Oncol, 1/1/1999
Extraovarian Primary Peritoneal Carcinoma
Gillette CN, DiSaia PJ, Oncol, 1/1/1998
Aortic Valve Replacement in the Elderly
Elayda MA, Hall RJ, Real RM, Gillette CN, Cooley DA, Circulation, 1/1/1993
Join now to see all

Abstracts/Posters

Ovarian Cancer in the Elderly: Trends in Survival over 30 years.
Tierney B, Crotzer D, Morris P, Cloven N., 41 st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco CA, 1/13/2010
Outcomes of intermediate risk endometrial cancer without whole pelvis radiation therapy.
Tierney BJ, Larsen G, Simons M, Crotzer D, Cloven NG, Morris PC, Western Association of Gynecologic Oncologists, Sonoma CA, 1/11/2008
Does thorough surgical staging eliminate the need for radiation therapy in high intermediate risk endometrial cancer?
Tierney BJ, Larsen G, Simons M, Crotzer D, Morris PC, Cloven NG, 39 th Annual Meeting of the Society of Gynecologic Oncologists, Tampa FL, 1/1/2008
Lymphadenectomy in Endometrial Cancer: What is the Right Number of Lymph Nodes?
Larsen G, Tierney BJ, Crotzer D, Cloven NG, Morris P, Western Association of Gynecologic Oncologists, Bend OR, 1/1/2007
Correlation of in vitro chemoresistance assays results and survival in patients with newly diagnosed ovarian cancer
Rice LA, Morris PC, Barsoom MJ, Cloven NG, Western Association of Gynecologic Oncologists, Santa Fe, NM, 1/1/2005
In Vitro Chemoresistance and Biomarker Profiles Are Unique for Histologic Subtypes of Epithelial Ovarian Cancer.
Cloven NG, Kyshtoobayeva A, Burger RA, Fruehauf JP, Society of Gynecologic Oncologists Thirty-third Annual Meeting, Miami Beach, Florida, 1/16/2002
Gene therapy of ovarian cancer in an immunocompetent rat using an adenovirus-mediated dominant negative receptor gene
Chan JK, Pham H, You XJ, Cloven NG, Burger RA, Rose GS, Van Nostrand K, Korc M, DiSaia PJ, Fan H, Thirtieth Annual Meeting of the Western Association of Gynecologic Oncologists, Sun Valley, Idaho, 1/6/2001
Evading drug resistance using a truncated EGF receptor in an immunocompetent rat model of ovarian cancer.
Chan JK, Cloven NG, Pham H, You XJ, Burger RA, Rose GS, Korc M, DiSaia PJ, Fan H., Thirtieth Annual Meeting of the Western Association of Gynecologic Oncologists, Sun Valley, Idaho, 1/6/2001
Bowel Resection at the Time of Primary Debulking For Epithelial Ovarian Cancer
Gillette Cloven N, Burger RA, McMeekin DS, Monk BJ, Manetta A, Berman ML, DiSaia PJ, Kohler MF., Thirty-second Annual Meeting of the Society of Gynecologic Oncologists, Nashville, Tennessee, 1/1/2001
Suppression of Ovarian Cancer Cell Tumorigenicity Using a Truncated EGF Receptor in an Immuno-Competent Rat Model.
Pham H, Chan JK, Gillette Cloven N, Burger RA, Rose GS, Van Nostrand K, Korc M, DiSaia PJ, Fan H., Annual Meeting of the Western Association of Gynecologic Oncologists, Monterey, California, 1/1/2000
Development and Characterization of a Cisplatin Resistant Epithelial Ovarian Cancer Cell Line in an Immuno-competent Rat Model.
Chan JK, Gillette Cloven N, Pham H, Burger RA, Rose GS, Korc M, DiSaia PJ, Fan H., Annual Meeting of the Western Association of Gynecologic Oncologists, Monterey, California, 1/1/2000
Evaluation of D-Methionine as a cytoprotectant in the Cisplatin Treatment of an Animal Model for Ovarian Cancer.
Gillette Cloven N, Re A, McHale M, Rose GS, Campbell K, Burger RA, Chan JK, DiSaia PJ, Fan H., Thirty-first Annual Meeting of the Society of Gynecologic Oncologists, San Diego, California, 1/1/2000
Retroviral Transduction of a Dominant Negative Epidermal Growth Factor Receptor into Ovarian Cancer Cell Lines.
Gillette Cloven N, Chan JK, Burger RA, Howoruszko A, Kathari N, Datta S, Bonzon C, Van Nostrand K, Rose GS, Fan H, Thirty-first Annual Meeting of the Society of Gynecologic Oncologists, San Diego, California, 1/1/2000
Retroviral Transduction of a Dominant Negative Epidermal Growth Factor Receptor into Ovarian Cancer Cell Lines
Gillette Cloven N, Chan JK Burger RA, Howoruszko A, Kathari N, Datta S, Bonzon C, Van Nostrand K, Rose GS, Fan H, Eighth International Conference on Gene Therapy of Cancer, San Diego California, 1/1/1999
Retroviral Transduction of a Dominant Negative Epidermal Growth Factor Receptor into Ovarian Cancer Cell Lines
Gillette CN, Chan JK, Burger RA, Howoruszko A, Kathari N, Datta S, Bonzon C, VanNostrand K, Rose GS, Fan H., AACR-NCI-EORTIC International Conference Molecular Targets and Cancer Therapeutics, Washington DC, 1/1/1999
Bowel Resection during Primary Surgical Debulking for Epithelial Ovarian Carcinoma.
Gillette CN, Kurosaki T, McMeekin DS, Burger R, Manetta A, Vasiley S, DiSaia PJ, Berman ML, Kohler MF., Western Association of Gynecologic Oncologists Annual Meeting, Jasper Alberta, Canada, 1/1/1997
Paclitaxel-associated Intestinal Complications in Patients with Ovarian Cancer.
Gillette CN, Burger RA, Kohler MF, Monk BJ, Seewaldt VL, Greer BE, Manetta A, Western Association of Gynecologic Oncologists Annual Meeting, San Diego, California, 1/1/1996
Join now to see all

Lectures

Personalized Medicine: The Future is here
Joan Katz Breast Center, Fort Worth, Tx - 9/25/2016
Robotic Surgery in Gynecology
Forth Worth, TX - 1/6/2011
Benign and Malignant Vulvar Diseases
Methodist Estabrook Cancer Center - 1/19/2008
HPV Testing and Cervical Cancer Screening
Las Vegas, Nevada - 1/14/2008
Future Directions in Gynecologic Oncology Surgery
Omaha Marriott Hotel Regency - 1/19/2007
Cervical cancer and the Hope of the HPV Vaccine
Methodist Cancer Center - 1/22/2006
What's New in Cervical Cancer Screening and Prevention
Las Vegas, Nevada - 1/1/2005
Cancer and the Female Patient: Hormone Replacement Therapy and Cancer Risk
Omaha, Nebraska - 1/10/2003
Hormones and Cancer Risks
Las Vegas, Nevada - 1/1/2003
Endometrial Cancer
Omaha, Nebraska - 1/12/2002
New Therapies in GYN Malignancies
Grand Island, Nebraska - 1/9/2002
In Vitro Drug Resistance Testing at Primary Debulking for Ovarian Cancer
Whistler, British Columbia - 1/1/2002
Para-aortic Lymph Node Metastasis in Cervical Cancer: Missed Opportunity for Cure?
Omaha, Nebraska - 1/16/2001
Facts and Myths Regarding GYN Oncology Screening
Las Vegas, Nevada - 1/1/2001
D-Methionine Allows for Dose Escalation of Cisplatin in the Treatment of an Ovarian Cancer Animal Model
Monterey California - 1/1/2000
New Therapeutic Strategies in Gynecologic Malignancies
UCI Medical Center, Department of Obstetrics and Gynecology - 1/1/1999
Management of Ovarian Cancer in Patients Older than 80 years of Age
Dana Point, California - 1/1/1999
Applied Surgical Anatomy
UCI Medical Center, Department of Obstetrics and Gynecology, Orange,California - 1/1/1998
Gynecologic Malignancies in the Elderly
UCI Medical Center, Department of Obstetrics and Gynecology, Orange,California - 1/1/1998
Intestinal Complications during Primary Surgical Debulking for Epithelial Cancer
Jasper Alberta, Canada - 1/1/1997
Paclitaxel-Associated Intestinal Complications in Patients with Ovarian Cancer
San Diego, California - 1/1/1996
Join now to see all

Authored Content

myths about gynecologic cancerSeptember 2019

Press Mentions

Medical Institutions, Physicians Push for Fort Worth to Become Top Clinical Research HubJuly 7th, 2024
Gynecologic Cancer Awareness Month Draws Attention to Disparities in Endometrial CancerSeptember 22nd, 2022
3 Questions to Ask Your Oncologist About Clinical TrialsAugust 31st, 2021
Join now to see all

Research History

Network PIPhase II study of Niraparib ( PARP) for recurrent ovarian cancer2014 - Present
Asssociate Chair of Gynecologic Cancer Committee2011 - Present